CClinicalTrials.gg
Not yet recruitingNCT04808947Updated Jul 16, 2025

LIA vs. LIA + ACB-iPACK Block for Total Knee Arthroplasty

An interventional study of Local infiltration analgesia and Ultrasound-guided adductor canal block in Nerve Block and Neuromuscular Blockade, sponsored by Women's College Hospital. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Women's College Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

LIA is the mainstay of postoperative analgesia in patients having knee arthroplasty. The combination of ACB-iPACK blocks has also been proposed as an effective analgesic modality for total knee arthroplasty. However, whether combining these two modalities yields any important incremental analgesic benefit remains unclear. The investigators hypothesized that the addition of ACB and iPACK blocks to LIA will yield clinically important analgesic benefits compared to LIA alone in patients having total knee arthroplasty.

Read the detailed description

LIA is the mainstay of postoperative analgesia in patients having knee arthroplasty. Performed by surgeons, LIA provides effective postoperative pain relief and reduces opioid requirements. Similar analgesic benefits have also been attributed to adductor canal and iPACK blocks, which partially block sensory innervation to the knee and its posterior capsule. Performed by anesthesiologist preoperatively, these blocks have also been incorporated into the care standard in numerous centers. However, it is not clear whether adding the adductor canal and iPACK blocks yields any incremental analgesic benefits. The investigators aimed to evaluate the benefits of adding adductor canal and iPACK blocks to LIA in patients having total knee arthroplasty.

02

Conditions studied

  • Nerve Block
  • Neuromuscular Blockade
03

In context

Lead sponsor

Women's College Hospital is the lead sponsor of 83 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. ASA classification I-III
  2. BMI \< 35 kg/m2
  3. Having elective unilateral total knee arthroplasty

Exclusion criteria

Exclusion Criteria:

  1. Bilateral knee surgery.
  2. Pre-existing neurological deficit or peripheral neuropathy in the lower the lower limbs
  3. Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases
  4. Severe, poorly controlled respiratory conditions (severe COPD, severe interstitial lung disease, severe / poorly controlled asthma)
  5. Contraindication to regional anesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)
  6. Patient refusal
  7. Chronic pain disorder
  8. Chronic opioid use (≥30 mg oxycodone / day)
  9. Contraindication (or allergy) to a component of multi-modal analgesia protocol
  10. Allergy to amide local anesthetics used in nerve blocks
  11. Contraindications to spinal anesthesia
  12. Significant psychiatric disorder that would preclude objective study assessment
  13. Pregnancy
  14. Inability to provide informed consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Local infiltration analgesia

    Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug.

    Procedure: Local infiltration analgesia

  • Active comparator
    Local infiltration analgesia + ACB-iPACK block

    Patients in this group will receive LIA intraoperatively, as per institutional standard. The injected solution will be comprised of 100cc Ropiv 2%, + Ketorolac 30 mg + Epinephrine 25 ug. Patients in this group will also receive preoperative nerve blocks under ultrasound guidance. These will include: 1. Adductor canal block with 0.5% Ropivacaine w/epi 20 mL 2. iPack block with 0.25% Ropivacaine w/epi 10 mL

    Procedure: Local infiltration analgesia · Procedure: Ultrasound-guided adductor canal block

Interventions

  • ProcedureLocal infiltration analgesia

    Procedure: Local infiltration analgesia performed by surgeons.

  • ProcedureUltrasound-guided adductor canal block

    Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.

    Also known as: iPACK block

06

What researchers measure

Primary outcomes

  1. Postoperative pain at rest

    Area under the curve

    Time frame: over the first 24 hours

  2. Quality of recovery (QoR-15)

    Quality of Recovery (QR15) scores at 24 hours will be the second primary outcome. QR15 is a measurement of quality of recovery after surgery and anesthesia that has been psychometrically tested and validated. Reporting of outcome measures on a scale of 0 to 10 (0=None of the time and 10=All of the time). There are a total of 40 items/questions.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Mean opioid analgesic consumption

    Postoperative cumulative oral morphine equivalent consumption during the first 24 hours

    Time frame: 24 hours postoperatively

  2. Time to first analgesic request

    Time frame: Up to 48 hours following surgery

  3. Pain Assessment (VAS)

    Visual Analogue Scale(VAS) - Pain:Overall pain assessed at rest and on movement A continuous scale comprised of a 100mm (10cm) horizontal line, anchored by 2 verbal descriptions No Pain to Worst Pain

    Time frame: at 0, 6, 12, 18 and 24 hours

  4. Risk of opioid-related side effects

    nausea, vomiting, pruritus, sedation

    Time frame: Up until one month following nerve block

  5. Block-related complications

    vascular puncture, hematoma formation, intravascular injection, epidural anesthesia-bilateral sensory block

    Time frame: Up until one month following nerve block

  6. Satisfaction with pain management

    A Patient Diary will be completed to assess overall satisfaction with analgesic technique 10 cm scale with "not satisfied at all" and "very satisfied" at either end

    Time frame: at 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kim DH, Beathe JC, Lin Y, YaDeau JT, Maalouf DB, Goytizolo E, Garnett C, Ranawat AS, Su EP, Mayman DJ, Memtsoudis SG. Addition of Infiltration Between the Popliteal Artery and the Capsule of the Posterior Knee and Adductor Canal Block to Periarticular Injection Enhances Postoperative Pain Control in Total Knee Arthroplasty: A Randomized Controlled Trial. Anesth Analg. 2019 Aug;129(2):526-535. doi: 10.1213/ANE.0000000000003794. PubMed 30234517 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04808947
Lead sponsor
Women's College Hospital
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Jan 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 16, 2025

Study contacts

Didem Bozak
Contact
didem.bozak@wchospital.ca
416-323-6008
Richard Brull, MD
principal investigator · Women's College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion